KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Accounts Payables: 2010-2025

Historic Accounts Payables for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $15.6 million.

  • Nektar Therapeutics' Accounts Payables rose 81.45% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 81.45%. This contributed to the annual value of $11.6 million for FY2024, which is 17.38% up from last year.
  • Nektar Therapeutics' Accounts Payables amounted to $15.6 million in Q3 2025, which was up 8.98% from $14.3 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Accounts Payables registered a high of $23.7 million during Q3 2021, and its lowest value of $2.6 million during Q2 2023.
  • Over the past 3 years, Nektar Therapeutics' median Accounts Payables value was $8.8 million (recorded in 2024), while the average stood at $9.3 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first crashed by 78.79% in 2023, then skyrocketed by 160.86% in 2024.
  • Nektar Therapeutics' Accounts Payables (Quarterly) stood at $9.7 million in 2021, then soared by 33.17% to $13.0 million in 2022, then declined by 24.13% to $9.8 million in 2023, then rose by 17.38% to $11.6 million in 2024, then spiked by 81.45% to $15.6 million in 2025.
  • Its Accounts Payables stands at $15.6 million for Q3 2025, versus $14.3 million for Q2 2025 and $17.8 million for Q1 2025.